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a b s t r a c t 
Introduction: Although efficacy of ustekinumab (UST) has been demonstrated through randomized trials, 
data from real-life prospective cohorts are still limited. Our aim was to evaluate clinical efficacy, drug 
sustainability, dose intensification and results from therapeutic drug monitoring in UST treated patients 
with Crohn’s disease (CD) using a prospective, nationwide, multicenter cohort. 
Methods: Patients from 10 Inflammatory Bowel Disease centers were enrolled between 2019 January and 
2020 May. Patient demographics, disease phenotype, treatment history, clinical disease activity (Crohn’s 
Disease Activity Index(CDAI), Harvey Bradshaw Index(HBI)), biomarkers, and serum drug levels were ob- 
tained. Evaluations were performed at week8 (post-induction), w16–20, w32–36, and w52–56 follow-up 
visits. 
Results: A total of 142 patients were included [57.4% female; complex disease behavior (B2/B3):48%, 
previous anti-TNF exposition:97%]. Clinical response and remission rates after induction(w8) were 78.1% 
and 57.7% using CDAI, and 82.5% and 51.8% based on HBI scores. The one-year clinical remission 
rate was 58%/57.3%(CDAI/HBI). Composite clinical and biomarker remission (CDAI < 150 and C-reactive 
protein < 10 mg/L) rates were 35.4%; 33.3%; 38.6% and 36.6% at w8/w16–20/w32–36 and w52–56. Drug 
sustainability was 81.9%(standard deviation(SD): 3.4) at 1 year(1y). Probability of dose intensification was 
high and introduced early, 42.2%(SD:4.2) at ~w32 and 51.9%(SD:4.4%) at 1y. 
Conclusion: Ustekinumab showed favorable drug sustainability and clinical efficacy in a patient popula- 
tion with severe disease phenotype and previous anti-tumor necrosis factor (anti-TNF) failure, however 
frequent dose intensification was required. 
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Treatment options for inflammatory bowel diseases (IBD) have 
mproved substantially in recent years with the introduction of rights reserved. 
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nti-TNF agents and selective anti-integrin therapy, however, a 
arge portion of patients with refractory disease (primary and 
econdary non-responders) still require novel therapeutic options. 
stekinumab is a fully human, immunoglobulin G1 monoclonal an- 
ibody that targets the standard p40 subunit of the IL-12 and IL-23 
ytokines. By binding p40, the activity of the IL-23 and IL-23 re- 
eptors, which are found on T cells, antigen-presenting cells and 
atural killer cells, is blocked, thus effecting a negative feedback 
n chronic immunological responses [1] . 
Ustekinumab demonstrated good efficacy in inducing clinical 
nd endoscopic remission in moderate-to-severe Crohn’s disease 
CD) patients in the UNITI 1 and UNITI 2 randomized controlled 
rials (RCTs), meanwhile, long-term efficacy and safety data of 96 
eeks follow-up have been reported in IM-UNITI [2 , 3] . Further- 
ore, good efficacy in the TNF α failure population was also shown 
n the CERTIFI trial [4] . 
Although efficacy and safety of ustekinumab have been well 
emonstrated through RCTs, patients enrolled in clinical trials are 
ot entirely representative of those treated everyday clinical prac- 
ice, thus data from real-life prospective cohorts are still of great 
nterest. Real-world experience allows bridging of some data gaps 
hat are lacking in RCTs, adding substantial information to clinical 
ractice on safety, efficacy, optimal treatment interval and dosing 
ased on unselected patient populations. 
Ustekinumab had been approved by both the US Food and Drug 
dministration and the European Medicines Agency for the treat- 
ent of CD in 2016, and it was adopted for general reimbursement 
y the National Health Insurance Fund of Hungary (NEAK) in Oc- 
ober 2018. 
The aim of the present study was to evaluate the clinical ef- 
cacy, drug sustainability, frequency of dose intensification, and 
esults from therapeutic drug monitoring in ustekinumab treated 
rohn’s disease patients based on a multicenter prospective cohort 
rom Hungary. 
. Materials and methods 
.1. Study design and patients 
This is a prospective multicenter observational study conducted 
t 10 Hungarian referral IBD centers (5 academic centers and 5 
ounty hospitals). Eligible patients with an age of 18 years or older 
nd receiving ustekinumab therapy were consecutively enrolled 
etween January 2019 and May 2020. 
For induction treatment, patients were given a single dose of 
stekinumab intravenous injection using a weight-based dosage 
egimen: 260 mg < 55 kg, 390 mg between 55 kg and 85 kg, and
20 mg > 85 kg. This was followed by subcutaneous (s.c.) injections 
90 mg) starting at week 8 (w8), and followed by s.c. injections 
very 12 weeks, constituting the maintenance treatment. In case 
f dose-intensification, s.c. injections were due every 8 or every 4 
eeks. 
A standardized monitoring strategy was applied in all partic- 
pating centers, as requested by the Hungarian National Health 
und. Data of patient demographics, disease phenotype, treat- 
ent history (surgical history, previous and present concomitant 
edications) were collected from the electronic medical records 
nd upon patient inclusion. Disease location and behavior were 
ssessed according to the Montreal classification [5] . 
Primary outcomes of the present study were evaluation of clin- 
cal disease activity and drug sustainability after a one-year follow- 
p period. Secondary outcomes included corticosteroid-free remis- 
ion rates, composite clinical and biomarker remission rates and 
ose intensification rates. Data on serum drug levels in available 
amples were also collected. 2 Evaluations of clinical disease activity and collection of data 
n biomarkers and therapeutic drug monitoring (if available) were 
erformed at baseline, w8 (post-induction), w16–20, w32–36, and 
52–56 (1-y) follow-up visits. Clinical disease activity was evalu- 
ted using the Crohn’s Disease Activity Index (CDAI) and Harvey 
radshaw Index (HBI) [6 , 7] . Infusion and injection related adverse 
vents were registered at baseline and at every follow-up visit. 
Baseline clinical disease activity was defined moderate-to- 
evere (CDAI > 220 or HBI > 7), mild (150 ≤CDAI ≤220 or 5 ≤HBI ≤7),
r clinical remission (CDAI < 150 or HBI < 5) based on these in- 
ices. Clinical response was defined as a decrease of CDAI by ≥70 
oints or decrease of HBI ≥3 points, respectively. Clinical remission 
as defined as a CDAI of less than 150 points, or an HBI score of
ess than 5 points. We chose to present the two most commonly 
sed clinical activity scores in CD simultaneously, as a sensitivity 
nalysis of our results. 
In fistulizing disease, remission was defined as no fistula 
rainage. Biomarker evaluation consisted of C-reactive protein 
CRP) measurement. Cut-off level for CRP was set at < 10 mg/L. 
he definition of corticosteroid-free remission was clinical remis- 
ion based on CDAI/HBI without any systemic corticosteroid med- 
cation at the time of the assessment. We calculated ‘composite 
linical and biomarker remission’ rates, defined by clinical remis- 
ion based on CDAI/HBI scores and CRP levels below cut-off. 
Serum drug trough level (TL) and anti-drug antibody (ADA) 
ere measured using enzyme-linked immunosorbent assay meth- 
ds (ELISA) by Lisa-Tracker ustekinumab Duo kit. (Theradiag, 
rance). All sample measurements were performed at the Depart- 
ent of Laboratory Medicine, Semmelweis University, Budapest. 
.2. Statistical analysis 
For the characterization of demographic data, remission and 
esponse rates, adverse events descriptive statistics were applied. 
edians and interquartile ranges (IQR) were calculated for contin- 
ous variables. Kaplan–Meier survival curves were used to evaluate 
rug sustainability and dose escalation. Log-rank test was used to 
ompare dose-escalation probabilities in patient subgroups. Statis- 
ical analysis was performed using SPSS software v. 20.0 (Chicago, 
L); P < 0.05 was considered statistically significant. 
.3. Ethical considerations 
Ethical approval of the study was acquired from the Hungar- 
an Medical Research Council’s Committee of Scientic and Research 
thics [ETT-TUKEB 20877-1/2019/EKU]. Consent forms of all pa- 
ients were obtained in accordance with the Helsinki Declaration. 
. Results 
.1. Description and initial clinical characteristics of the cohort 
A total of 142 CD subjects were consecutively included with 
 median follow-up time of 60 weeks (IQR: 47.5–79.5), 56.3% of 
hem were female, mean age was 38.4 ± 13.0 years. Complex 
isease phenotype (B2-B3) was present in 48.2%, whereas ileo- 
olonic disease location (L3) in 55.7%, and perianal manifestation 
n 46.8% of the patients. Prior resective and perianal surgical his- 
ory was 45.4% and 46%, respectively. Previous anti-TNF exposition 
as 97.2%, while previous vedolizumab failure was 25.5%. Detailed 
atient characteristics are shown in Table 1 . 
Median clinical disease activity score at baseline was 270 
IQR: 189-323) based on CDAI, and 10 (6-15) using HBI score. 
6.2% / 66.9% of the patients had moderate-to-severe clinical dis- 
ase activity at inclusion (CDAI > 220/HBI > 7). 19.7% / 16.9% of the 
tudy population had mild clinical disease activity at inclusion 
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Table 1 
Baseline characteristics of the study individuals. 
CD ( n = 142) 
Gender (male/female; n) 62 (43.7%) / 80 (56.3%) 
Age at disease onset (mean (SD); y) 25.6 (11.0) 
Age at inclusion (mean (SD); y) 38.4 (13.0) 
Disease duration (median (IQR); y) 12.5 (8.0-18.0) 

















Perianal manifestation (%) 46.8 
Previous surgical resection (%) 45.4 
Previous perianal surgery (%) 46.0 
Previous immunosuppressive therapy (%) 80.9 
Previous anti-TNF therapy (%) 
NO previous anti-TNF 2.8 
IFX 14.2 
ADA 19.9 
IFX + ADA 63.1 
Previous vedolizumab therapy (%) 25.5 
Concomitant immunosuppressive therapy at 
baseline (%) 
20.2 
Concomitant corticosteroid therapy at baseline (%) 34.0 
Median follow-up time (IQR; weeks) 60 (47.5–79.5) 
(CD: Crohn’s disease, SD: standard deviation, IQR: interquartile range, anti-TNF: 













































































150 < CDAI < 220 / 5 ≤HBI ≤7), and 14.1% / 16.1% were in clinical re-
ission (CDAI < 150/HBI < 5) at inclusion. Of note, parallel systemic 
orticosteroid medication was present in as high as 34.0% of the 
atients at baseline. 
.2. Clinical response and remission rates 
Eight weeks after the induction therapy, 78.1% of the total 
tudy population showed clinical response as per CDAI, and 57.7% 
ere in clinical remission. As per HBI these numbers were 82.5% 
nd 51.8%, respectively. When separately analyzing patients with 
oderate-to-severe disease activity at baseline, clinical response 
ates were 78.9%/78.9% using CDAI or HBI scores, however only 
0.0% / 35.5% (CDAI/HBI) of these individuals were in clinical 
emission. During the maintenance phase, clinical remission 
ates at half year (week 32-36) were 54.9% / 56.5%, while one 
ear clinical remission rates were 58% / 57.3% (CDAI/HBI). For 
etailed results see Fig. 1 . Clinical remission rates in patients with 
oderate-to-severe disease activity at baseline were consequently 
ower throughout the study period, 50% / 35.5% at w8; 62.6% / 
0.6% at w16-20; 46.9% / 44.3% at w32–36; and 47.1% / 50% at 
ne year (CDAI/HBI). In a subgroup-analysis, patients with mild or 
o clinical disease activity at baseline presented clinical remission 
ates of 72.3% / 84.2% at w8; 70.7% / 83.8% at w32–36; and 58.6%
 68.4% at one year (CDAI/HBI). 
Notably, a significant proportion of patients received concomi- 
ant systemic corticosteroid therapy at baseline (34.0%), and 26.3% 
t post-induction (w8). At week 32–36 21.0%, and at one year still 
6.9% of the patients received systemic corticosteroids. (see Sup- 
lementary Table 1). Steroid-free clinical remission rates of the 3 otal cohort are detailed in Fig. 2 . In patients with moderate-to- 
evere disease activity at baseline, remission rates were conse- 
uently lower: 33.3% / 24.3% at w8; 53.4% / 43.6% at w16–20; 
0.3% / 39.1% at w32–36; and 50.8% / 47.5% at one year (CDAI/HBI). 
We also evaluated drug efficacy using a combined criteria of 
linical score remission and normalized biomarker levels (CRP). 
omposite clinical and biomarker remission rates (CDAI < 150 and 
RP < 10mg/L) were 35.4%, 33.3%, 38.6%, and 36.6% by week 8, w16–
0, w32–36, and w52–56, respectively ( Fig. 3 ). Composite clinical 
nd biomarker remission rates in patients with moderate-to-severe 
isease activity at baseline were as follows: 30.7%, 29.1%, 31.9%, 
nd 40% by week 8, w16–20, w32–36, and w52–56, respectively. 
Analyzing the patients according to their prior biological 
herapy revealed a tendency to lower clinical efficacy in case of 
ultiple previously failed biologicals. For detailed composite clin- 
cal and biomarker remission rates stratified by previous biological 
xposure see Supplementary Fig. 1. 
.3. Dose intensification and drug sustainability 
Drug sustainability was high with 90.4% (SD: 2.5) of the pa- 
ients remaining on treatment at week 32, and 81.9% (SD: 3.4) at 
ne year. ( Fig. 4 /A) Overall n = 23 patients discontinued therapy 
uring our follow-up (loss of response: n = 14; pregnancy: n = 4; 
ide effect: n = 2; lost to follow-up: n = 3). Probability of dose 
ntensification (Q8 or Q4 regimens) was high and introduced early 
n the treatment, 42.2% (SD: 4.2) at week 32 and 51.9% (SD: 4.4%) 
t one year ( Fig. 4 /B). Q8 dosing regimens were introduced in 61 
atients (43.0%) during our follow-up, while 16 patients (11.3%) re- 
eived a subcutaneous dose every 4 weeks. Patients with complex 
isease phenotype (B2/B3) had higher probability for dose intensi- 
cation (Log-rank: 4.17; p = 0.042). A similar trend could be ob- 
erved in patients with perianal manifestation, who required dose 
ntensification more frequently (Log-rank: 2.22; p = 0.136). 
.4. Adverse events 
No serious adverse events were observed in our cohort. Two 
ubjects discontinued therapy due to adverse events: one case of 
rthralgia and another patient with recurrent skin erythema at the 
njection site. Skin reaction at injection site was reported by two 
ther patients, and one patient reported hair loss. All three pa- 
ients continued treatment. No allergic reactions were detected at 
he time of intravenous infusions. 
.5. Therapeutic drug monitoring 
Data from n = 58 serum drug level and anti-drug anti- 
ody measurements were available. Mean serum trough levels of 
stekinumab were 4,28 ± 3,35/ 1,35 ± 1,42/ 0,82 ± 0,65 and 
,13 ± 0,74 μg/mL measured at w8/w16–20/w32–36 and w52–56 
ollow-up visits. ( Fig. 5 ) ADAs were exceeding 1AU/mL in only 2 
atients. 
. Discussion 
The results of this current prospective multicenter study pro- 
ide additional post-marketing data on the efficacy and safety of 
stekinumab in unselected patients of a ‘real-world’ setting. We 
lso show data on the medium-term drug sustainability and the 
robability of dose-intensification in a heavily burdened patient 
opulation with a high rate of complex disease phenotype and vir- 
ually 100% of previous anti-TNF treatment failure. 
Ustekinumab showed good short- and medium-term clinical 
esponse and remission rates, corticosteroid-free and composite 
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Fig. 1. Clinical response and remission rates based on CDAI and HBI scores. 
Fig. 2. Corticosteroid-free clinical remission rates. 
Fig. 3. Composite clinical and biomarker remission rates (CDAI / HBI score remission and CRP < 10 mg/L). 
Fig. 4. Drug sustainability (A) and probability of dose intensification (B) in Kaplan–Meier analyzis. 
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clinical + biomarker /CRP/) remission rates in this biologic- 
xposed population. After 52 weeks, 58.0%, 51.1% and 36.6% of 
ll patients were in clinical, corticosteroid-free clinical, and com- 
ined clinical and biomarker (CRP) remission, respectively. In 
omparison, in the IM-UNITI registration trial, 41.1% achieved 
linical remission at week 44 using anti-TNF refractory patients 
nly (from UNITI-1). Corticosteroid-free remission rates were 
6.9% at week 44 of the total population (IM-UNITI) [2] . In the 
ERTIFI clinical trial of anti-TNF resistant Crohn’s disease patients, 
lucocorticoid-free remission at week 22 was 30.6% [4] . However, 
nly patients with moderate-to severe baseline clinical activity 
nd a clinical response at post-induction were included in these 
nalyses as a consequence of clinical trial design, in contrast to 
ur ‘real-life’ cohort that analyzed all patients. 
When interpreting remission rates in clinical efficacy using 
real-life’ cohorts, one must take into account the proportion of pa- 
ients with mild or no clinical disease activity at baseline. In our 
ohort, baseline disease activity was mild or in remission up to 
35% of the patients. This relatively high rate of patients with mild 
r no symptomatic disease activity can be explained by the use of 
oncomitant corticosteroid to treat disease flare, before the initi- 
tion of biological therapy, or by biological treatment change due 
o adverse events, or simply by the known discrepancies between 
ndoscopic / biomarker disease activity and clinical symptoms in 
ome patients. 
Our results are comparable to published data from other 
nselected, mainly retrospective studies, however, prospective 
real-life’ cohorts are still limited, to date. A prospective multicen- 
er study from the Netherlands included 221 CD patients (98.6% 
nti-TNF and 46.6% vedolizumab exposed) with a median follow- 
p of 52 weeks. At baseline, a proportion of the patients (30.8%) 
ere in clinical remission based on the clinical indices, but had 
iomarker or endoscopic activity, similarly to the present cohort. 
orticosteroid-free clinical remission rates in this study were com- 
arable to our results, and similar sub-analyses were carried out 
xcluding patients without clinical activity at baseline. For patients 
ith active disease at baseline, remission rates were 24.2%, 38.2% 
nd 37.1% at weeks 12, 24 and 52, respectively. When analyzing all 
atients regardless of clinical disease activity at baseline [ n = 221], 
he proportion of patients in corticosteroid-free clinical remission 
t weeks 0, 12, 24 and 52 were 25.8%, 35.7%, 46.6% and 41.8%, re-
pectively [8] . Very recently, the two-year effectiveness and safety 
esults of this prospective Dutch registry have been published 
9] . Of all included patients [ n = 252], corticosteroid-free clinical 
emission rates were 32.3%, 41.4%, 39% and 34.0%, at week 12, 24, 
2 and 104, respectively. In patients with combined clinical and 
iomarker disease activity at baseline [ n = 122] the corticosteroid- 
ree clinical remission rates were 23.8%, 35.2%, 40.0% and 32.8% 
t week 12, 24, 52 and 104, respectively. These figures correlate 
ell with our findings, namely around ~40% of the patients reach 
teroid-free remission at 1 year. The probability of remaining on 5 stekinumab treatment after 52 and 104 weeks in all patients was 
4.3% and 54.8%, and no new safety issues were observed. 
A smaller Canadian prospective cohort [ n = 62] of anti- 
NF refractory or intolerant patients showed very good clinical 
ffectiveness (66.1 and 50.0% clinical and corticosteroid-free 
linical remission at week 26), however, a very high portion of 
atients were on a q4w dosing interval (77.4%), and no anti- 
ntegrin exposed patients were included [10] . A recent prospective, 
ulticenter Israeli study evaluated short-term clinical outcomes in 
stekinumab-treated CD patients. Both anti-TNF and vedolizumab 
xposure was as high as 63% in this cohort. Clinical response was 
bserved in 52%, while clinical remission was achieved in 31.1% of 
he patients at week 24 [11] . More recently, results from a Sicilian 
D cohort were published with a total of 131 patients. Steroid-free 
linical remission rates at 24 and 52 weeks of follow-up were 40% 
47/117) and 43% (33/76) [12] . 
In addition, a large retrospective multicenter national cohort 
tudy from Belgium included 152 patients, all having been previ- 
usly exposed to at least one anti-TNF agent, and 69.7% to even 
wo anti-TNF and vedolizumab. After 1 year, clinical efficacy re- 
ults were more modest, with 25.7% of patients experiencing clini- 
al remission, and 24.3% steroid-free clinical remission, respectively 
13] . Another retrospective chart review study, called FINUSTE2, 
aptured data at 17 Finnish hospitals ( n = 155 CD patients, ~66% 
xposed to two or more biological) and reported a corticosteroid- 
ree biomarker remission rate of 41.4% at 1 year [14] . Finally, the 
panish retrospective ENEIDA registry presents results on a total 
f 407 patients, of whom only 4% had not been previously treated 
ith anti-TNF α agents. Of the patients with clinical disease activ- 
ty at baseline ( n = 295), 57% and 64% achieved clinical remission 
t weeks 26 and 52, respectively [15] . 
A systematic review and pooled analysis of retrospective stud- 
es were carried out by Engel et al. on the real-world efficacy of 
stekinumab in anti-TNF failure patients. 578 patients of 6 eligible 
tudies were pooled for analysis, excluding RCT cohorts and stud- 
es missing well-reported efficacy data on long-term maintenance. 
ooled clinical response rate was 60%, 62%, and 49% at 12, 24 and 
2 weeks, respectively, while pooled clinical remission rate was 
9% at 24 weeks and ~28% at 52 weeks (data of only two studies, 
ot adequate for pooled statistical analysis). Steroid-free response 
ates, based on 4 cohorts with a total of 261 patients, yielded a 
ooled proportion of 51% at one year [16] . 
It is important to point out that relatively high rates of con- 
omitant systemic corticosteroid therapy were observed in our 
tudy with 34% of the patients receiving steroids at baseline, 26% 
t the end of induction, and 17% after one year. However, simi- 
arly high steroid need was observed in other cohorts comprising 
atients with multiple previous biological treatment failures. In a 
panish multicenter cohort, 35.1% of the patients received systemic 
orticosteroids at the time of ustekinumab introduction [17] . In the 
sraeli prospective cohort, 34.9% of the patients were treated with 
ystemic steroids at induction, which decreased to 15% at week 
4 [11] . In another multicenter cohort from Belgium, concomitant 
teroids at induction were high with 44.7% at baseline [including 
0.1% of systemic steroids (methylprednisolone) and 29.9% of oral 
ontrolled-release formulation (beclomethasone or budesonide)]. 
y one year of follow-up, a progressive steroid weaning was ob- 
erved: 34.2% at week 8, 17.1% at week 16 and 11.2% at week 52 
13] . 
An advantage of the present study was that composite clinical 
nd biomarker remission rates were provided using CRP levels 
o more accurately identify patients in remission. The rate of 
omposite remission was ~35% post-induction, which was then 
aintained during the one-year follow up. Very few studies pro- 
ide similar endpoints, one of them is the previously mentioned 
rospective multicenter study by Biemans et al., which applies 
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ven stricter criteria by using steroid-free remission and a cut-off
alue of ≤5 mg/L for CRP. The proportion of patients in combined 
orticosteroid-free clinical and biomarker remission at weeks 12, 
4 and 52 was 5.2%, 13.9% and 18.2%, respectively [8] . We also 
tratified composite clinical and biomarker remission rates by 
revious biological exposure and showed trends to progressively 
eakening efficacy, as expected in a population with multiple 
iological failures. 
We detected very high rates of drug sustainability in our co- 
ort, with 82% of the patients remaining on treatment after the 
rst year. Lower rates were reported in the prospective cohort by 
iemans et al. The probability of remaining on ustekinumab treat- 
ent after 52 weeks was 62.9% in survival analysis [8] . A multicen- 
er retrospective cohort from Spanish IBD centers included therapy 
esistant CD patients ( n = 116), with 2 or more previous anti-TNF 
ailures in 87% of the subjects. The cumulative probability for drug 
urvival at 6 and 12 months was 86% (95% CI: 83.1–88.9) and 74% 
95% CI: 70.3–77.7), more similar to the present study [17] . 
The rate of dose intensification was high and introduced early 
n the treatment, with 42.2% of the patients receiving Q8 or Q4 
egimens at week 32 in our cohort. Other cohorts of patients with 
ultiple previous treatment failures present even higher dose es- 
alation rates. In the Dutch cohort discussed above, at week 12 al- 
eady 65.0% continued their maintenance interval with injections 
very 8 weeks or less. At week 24, 77.3%, while at week 52, 85.2%
f the patients received the injection every 8 weeks or less [8] . 
lso very high rates of dose escalation are reported in studies from 
pain and Canada [17 , 10] . In a meta-analysis of earlier / retrospec-
ive cohorts, dose escalation rates reached only a pooled rate of 
5.6% [16] . Of note, comparing dose intensification rates is very 
ifficult, as it is dependent on the disease severity of the cohorts 
n question and also sensitive to reimbursement regulations con- 
tantly changing by countries and time. 
‘Real-world’ evidence data often suggest higher clinical efficacy 
nd drug survival rates compared to RCTs. This discrepancy is most 
ikely due to a less strict definition of clinical response/benefit in 
real-world’ studies. For many patients in this population, ustek- 
numab was the ‘last resort’ therapeutic option. Of note, the avail- 
bility of vedolizumab in our study was somewhat limited due 
o reimbursement regulations in Hungary, therefore previous ex- 
osure to vedolizumab was relatively low (~25%). Almost 50% of 
he patients had a stricturing or penetrating disease behavior, 
nd ~45% had perianal manifestations (21.3% having a seton at 
aseline). Under these circumstances, it is somewhat natural that 
stekinumab treatment could have been extended in some patients 
ven without clear evidence of benefit, and treatment discontinu- 
tion rates could have been higher if additional lines of therapy 
ere available. 
No serious adverse events, and only two instances of discontin- 
ation due to adverse events were observed in our cohort, which 
orrelates the favorable safety profile of ustekinumab previously 
eported 8 , 9 , 11] . Information on serum drug levels and anti-drug
ntibodies was only available in a limited number of patients in 
he present cohort. Recent data of meta-analysis from Phase 3 
tudies suggest that drug levels were proportional to Q12 and Q8 
osing regimen and reached a steady state by the second main- 
enance dose. Trough concentrations of ustekinumab of 0.8 g/mL 
r greater were associated with maintenance of clinical remission. 
ST antibodies were found in 2.3% of patients [18] 
The strengths of our study include a robust unselected prospec- 
ive design with nationwide harmonized monitoring practices 
cross all participating centers. Although evidence from real-world 
enters supports the efficacy and safety of ustekinumab therapy in 
D, studies from multicenter cohorts with prospective follow-up, 
specially in biological exposed patient populations, are still lim- 
ted in the literature. Limitations to our study are the lack of data 6 n endoscopic activity and fecal calprotectin, and the limited avail- 
bility of blood samples for serum ustekinumab level assessment. 
In conclusion, ustekinumab showed good clinical effectiveness 
n a real-life multicenter cohort of multiple biological exposed CD 
atients with high rates of complex disease phenotype. A substan- 
ial proportion of the patients achieved corticosteroid-free clinical 
emission and composite clinical and inflammatory biomarker re- 
ission in this one-year prospective follow-up. The rate of dose 
ntensification was high and it was introduced early in treatment, 
oupled with high rates of drug survival after one-year, reflecting 
 patient population predominantly receiving second or third line 
iological therapy. 
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